PCT/AU2013/000481 ‘Colvera™ panel for Colorectal Cancer’
After a 10-year discovery and validation clinical research project, Clinical Genomics scientists collaborating with the CSIRO and Flinders University in Australia co-discovered a number of epigenetically modified gene targets that only show chemical modification in early cancerous and precancerous lesions. We have now proven that these modified genes can leak into the blood of people with an invasive tumor, which we have used to develop a blood test for cancer.
The key breakthrough for this work was to discover disease targets that leak into the blood of people with cancer but not people who don’t have cancerous tumors.
The Colvera™ panel of BCAT1 and IKZF1 (so named because two of these gene markers) form the basis of Clinical Genomics’ next generation blood plasma test for colorectal cancer screening.
PCT/AU2011/001371 ‘Recovering Exosomes by Disruption’
In 2011, Clinical Genomics filed the ‘Disruption Patent’ describing a simple method for measuring RNA biomarkers in circulating whole blood that may be protected within microvessicles such as exosomes. This invention was developed with pathology processing in mind.
This technology, equally useful for simplifying upstream handling for microRNA and mRNA biomarkers, requires no high-speed ultracentrifugation or complex isolation steps.
PCT/AU99/00310 ‘The Brush Patent’
In 2002, Clinical Genomics was awarded a patent for collecting a water sample for colorectal cancer screening using a long-handled nylon brush.
Effectively a child’s paintbrush, this simple but elegant invention enables Clinical Genomics to deliver the most user-friendly form of sample collection for any screening kit. The disposable brush allows an individual to undergo a cancer screening without the need for fecal handling by collecting a sample of toilet bowl water from around the stool.